Immutep completes A $ 60 million placement to expand its

0

Sydney, AUSTRALIA, June 21, 2021 (GLOBE NEWSWIRE) – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or VSbusiness), is pleased to announce that it has received commitments for a private placement of A $ 60 million in two tranches of new ordinary shares (New actions) professional, institutional and informed investors (Placement).

The first tranche of the Placement will be carried out without the approval of the shareholders. The second tranche of the Placement is subject to shareholder approval.

The use of Funds
The Company will use the proceeds received from the placement to fund the expansion of its clinical programs and to begin characterization and validation of processes for the commercial manufacture of efti (2000 liter scale). The proceeds received from the Placement will also be used for the costs of the Offering and for working capital purposes.

Placement
The Placement will involve the issuance of New Shares at an issue price of AUD 0.52 per New Share (representing a discount of 12.9% from the volume weighted average price (VWAP) ordinary shares of the Company traded on the ASX during the 30 days until June 16, 2021 inclusive). The New Shares issued within the framework of the Placement will rank pari passu with the ordinary Immutep shares existing at issue from their date of issue.

The settlement of the first tranche of the Placement is expected to take place on June 25, 2021, and the issuance of New Shares is expected to take place on June 28, 2021.

Assuming shareholder approval is obtained to complete the second tranche of the offering, settlement is expected to occur on July 29, 2021, and the issuance of new shares is expected to occur on July 30, 2021.

Share Pbuy Plocal network
Following the completion of the issue of the first tranche of the Placement, Immutep will proceed with an offer of New Shares as part of an unsubscribed share purchase plan (SPP) to existing shareholders of the Company with registered addresses in Australia and New Zealand at 7:00 p.m. (Sydney time, Australia) on June 18, 2021.

The SPP will offer each Eligible Shareholder the possibility of requesting up to A $ 30,000 in New Shares at the price payable per New Share under the Placement. The PSP aims to raise around AU $ 5 million. The SPP is scheduled to close at 5:00 p.m. (Sydney, Australia time) on July 22, 2021.

About Immutep
Immutep is a globally active biotechnology company, a leader in the development of immunotherapeutics related to LAG-3 for the treatment of cancer and autoimmune diseases. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value. Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-class antigen-presenting cell (APC) activator currently being explored in the world. cancer and infectious diseases. Immutep is also developing an LAG-3 agonist (IMP761) for autoimmune diseases. Other LAG-3 products, in particular antibodies for modulating the immune response, are under development by Immutep’s major pharmaceutical partners.

Further information can be found on the company’s website www.immutep.com or by contacting:

American media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States. The New Shares which will be offered and sold under the Placement and the SPP have not been and will not be registered under the US Securities Act of 1933 (the “U.S. Securities Law“), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold to persons in the United States or to US Persons (as defined in Rule 902 (k) of Regulation S under the US Securities Act), with the exception of transactions registered under the US Securities Act or transactions exempted or not subject to the registration requirements of the US Securities Act and applicable US state securities.

This announcement contains certain “forward-looking statements”, including statements concerning the intention, belief or current expectations of the Company regarding the business and operations of Immutep, market conditions, results of operations, financial situation. financial and risk management practices. The words “likely”, “expect”, “aim”, “should”, “could”, “could”, “anticipate”, “foresee”, “believe”, “plan” and other similar expressions are intended to identify future forward-looking statements. Indications and indications of future earnings, financial condition and performance are also forward-looking statements. The forward-looking statements contained in this announcement include statements regarding the results and effects of the Offering and the SPP and statements regarding the financial performance and future results of Immutep. Forward-looking statements, including projections, indications of future earnings and estimates, are provided for guidance only and should not be taken as an indication or guarantee of future performance. This announcement contains such statements which are subject to the risk factors associated with an investment in the Company. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performance or achievements of the Company to be materially different from future results, performances or achievements expressed or under. – understood by these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this announcement.


Source link

Leave A Reply

Your email address will not be published.